Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to demonstrate improved survival in heavily treated patients with relapsed/refractory multiple myeloma, according to updated results from the phase 2 KarMMa trial (NCT03361748) presented at the 2021 ASCO Annual Meeting. During the trial, 140 patients with at least three prior lines of treatment for multiple myeloma who […]
